Drug name
Last update: Oct 2026GS-3107
Developer(s)
Drug information
Not provided
GS-3107 (oral lenacapavir prodrug)
Not applicable (investigational; no brand name assigned)
Small molecule
Capsid inhibitor — Capsid inhibitor
Active / In Development (Phase 1/2/3)
GS-3107 is an investigational long-acting capsid inhibitor. It is an oral prodrug of lenacapavir. This capsid inhibitor is designed to convert to lenacapavir after oral administration, but with a pharmacokinetic profile engineered to increase oral bioavailability and support once-monthly oral dosing. The approach of using prodrug to optimise bioavailability is being used when parent molecules have limited oral absorption. By increasing oral bioavailability, lower doses are needed, which means smaller pills (including in fixed-dose combinations). It is intended as the oral component of a once-monthly oral treatment regimen with an integrase inhibitor partner still to be defined; a paediatric HIV-1 treatment study is also planned according to the company pipeline.
Investigational
The product is still in development.
Therapeutic area(s)
- HIV
- Pre-Exposure Prophylaxis (PrEP)
- Treatment
Administration route
Oral
Associated long-acting platforms
Oral solid form
Use of drug
- Self-administered
- Administered by a community health worker
- Monthly
- Other/Variable/Unknown : To be determined based on clinical development
Dosage
Once-monthly oral dosing is the development target. Unclear whether the indication would be for treatment or prevention.
Not provided
Not provided
Not provided
Not provided
Additional information
Developer(s)
Gilead
Drug structure
Scale-up and manufacturing prospects
unknown as of October 2026
Not provided
Not provided
Not provided
Excipients & delivery device(s)
Not provided
Not provided
Not provided
Not provided
Safety, Efficacy and Evidence Summary
Unknown. This prodrug of lenacapavir just entered Phase I.
Not provided
Not provided
Not provided
There are either no relevant patents or these were not yet submitted to LAPaL